These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 8529526

  • 1. Outer membrane alterations in Pseudomonas aeruginosa after five-day exposure to quinolones and carbapenems.
    Cipriani P, Giordano A, Magni A, Papa F, Filadoro F.
    Drugs Exp Clin Res; 1995; 21(4):139-44. PubMed ID: 8529526
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem.
    Sakyo S, Tomita H, Tanimoto K, Fujimoto S, Ike Y.
    J Antibiot (Tokyo); 2006 Apr; 59(4):220-8. PubMed ID: 16830889
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates.
    El Amin N, Giske CG, Jalal S, Keijser B, Kronvall G, Wretlind B.
    APMIS; 2005 Mar; 113(3):187-96. PubMed ID: 15799762
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model.
    Zinner SH, Vostrov SN, Alferova IV, Lubenko IY, Portnoy YA, Firsov AA.
    Int J Antimicrob Agents; 2004 Aug; 24(2):173-7. PubMed ID: 15288317
    [Abstract] [Full Text] [Related]

  • 12. Resistance emergence among P. aenrginosa in a rat thigh-abscess model. Comparison of imipenem and meropenem treatment.
    Karadenizli A, Kolayli F, Okay E, Ergen K, Oz S, Savli H, Leblebicioglu H, Vahaboglu H.
    New Microbiol; 2003 Jul; 26(3):275-80. PubMed ID: 12901424
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Morphological changes induced by imipenem and meropenem at sub-inhibitory concentrations in Acinetobacter baumannii.
    Bernabeu-Wittel M, García-Curiel A, Pichardo C, Pachón-Ibáñez ME, Jiménez-Mejías ME, Pachón J.
    Clin Microbiol Infect; 2004 Oct; 10(10):931-4. PubMed ID: 15373891
    [Abstract] [Full Text] [Related]

  • 17. Emergence of quinolone-imipenem cross-resistance in Pseudomonas aeruginosa after fluoroquinolone therapy.
    Aubert G, Pozzetto B, Dorche G.
    J Antimicrob Chemother; 1992 Mar; 29(3):307-12. PubMed ID: 1317371
    [Abstract] [Full Text] [Related]

  • 18. In vitro activity of meropenem in combination with ciprofloxacin against clinical isolates of Pseudomonas aeruginosa.
    Solak S, Willke A, Ergönül O, Tekeli E.
    Int J Antimicrob Agents; 2005 Feb; 25(2):181-2. PubMed ID: 15664492
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Antimicrobial susceptibility of Pseudomonas aeruginosa isolated from urine at one hospital to mainly carbapenem and fluoroquinolone drugs].
    Watanabe Y, Fujiue Y, Yano S, Shimizu S, Muroki K, Doi M, Kuwabara M.
    Jpn J Antibiot; 2006 Apr; 59(2):65-71. PubMed ID: 16805317
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.